For example, in a therapeutic proof‐of‐principle experiment in the field of prostate cancer, we found that the SRPK1 inhibitors were able to inhibit phosphorylation of SR proteins and switch VEGF‐A splicing in vitro6. This evidence concerns the gene VEGFA and prostate carcinoma.